KE
K J Ewer
GlaxoSmithKline (United Kingdom), University of Oxford
Research areas: Medicine · Infectious Diseases · Malaria Research and Control · Immunotherapy and Immune Responses · SARS-CoV-2 and COVID-19 Research
0000-0001-9827-9836
Employment
-
GlaxoSmithKline (United Kingdom) Senior Project Leader, second generation malaria vaccines2023 - Present
-
GlaxoSmithKline (United Kingdom) Senior Project Leader, malaria vaccines2023 - Present
-
University of Oxford Professor of Vaccine Immunology2008 - 2023
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (141)
- Phase I/IIa study to assess the safety, immunogenicity and efficacy of ChAdOx1-MVA vectored vaccines expressing a novel liver-stage malaria dual antigen LS2 by sporozoite challenge in malaria-naïve adults [version 2; peer review: 2 approved, 2 approved w… Save
- A phase 1b clinical trial to determine the safety, tolerability and immunogenicity of simian adenovirus and poxvirus vectored vaccines against a Mycobacterium avium complex subspecies in patients with active Crohn's disease. Save
- The anti-circumsporozoite antibody response to repeated, seasonal booster doses of the malaria vaccine RTS,S/AS01E. Save
- Adaptive clinical trial of AZD7442 and SARS-CoV-2 vaccination in immunosuppressed patients highly vulnerable to infection with SARS-CoV-2 virus (RAPID-PROTECTION): protocol for a multicentre, interventional open-label, randomised controlled trial. Save
- Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials. Save
- R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18-45 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection study. Save
- Validation of a multiplexed immunoassay for immunological analysis of pre erythrocytic malaria vaccines. Save
- Repertoire, function, and structure of serological antibodies induced by the R21/Matrix-M malaria vaccine Save
- R21/Matrix-M Protects Against Dermal but not Against Venous Parasites in Human Challenge Studies Save
- A randomised trial of malaria vaccine R21/Matrix-M™ with and without antimalarial drugs in Thai adults. Save
- Validation of a multiplexed immunoassay for use in vaccine clinical trials and immunology studies of pre-erythrocytic malaria Save
- High-resolution African HLA resource uncovers HLA-DRB1 expression effects underlying vaccine response. Save
- Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. Save
- The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study. Save
- Safety and immunogenicity of varied doses of R21/Matrix-M™ vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya Save
- Correlations between three ELISA protocols measurements of RTS,S/AS01-induced anti-CSP IgG antibodies. Save
- Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial. Save
- Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials. Save
- A tool for evaluating heterogeneity in avidity of polyclonal antibodies. Save
- Impact of exposure to malaria and nutritional status on responses to the experimental malaria vaccine ChAd63 MVA ME-TRAP in 5-17 month-old children in Burkina Faso. Save